YTS109 cell therapy for hard-to-treat autoimmune diseases
Treatments studied
Part of Bones, joints & muscles, Brain & nervous system, Heart & circulation, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with one of the following that has not improved with standard treatments: lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, or antiphospholipid syndrome.
- Your blood counts, liver, kidney, and heart function are within the study's limits.
- You are not pregnant or breastfeeding, and you agree to use birth control for at least 12 months after treatment.
- You do not have a current serious infection, recent cancer, or certain heart or blood clotting issues.
- You are willing to stop other autoimmune medications for a period before starting this trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This trial tests a new type of cell therapy (YTS109 cells) for people with severe lupus that hasn't been controlled by standard treatments. The goal is to see if these cells can help calm the immune system and improve lupus symptoms.
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
This trial tests a new cell therapy called YTS109 for people with several autoimmune diseases that have not improved with standard medications. It aims to see if this treatment can help control the disease when other treatments have failed.
Hear when a new Inflammatory Myopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.